PTGS2 and colonic neoplasm: Clinical studies have noted a reduced risk for breast, lung, prostate, and colon cancers after treatment with non-selectively COX-2 inhibition by non-steroidal anti-inflammatory drugs (NSAIDs) or selective COX-2 inhibition with COX-2 inhibitors [10, 11].